Tuberculosis (TB) is a global pandemic, and multi-drug resistant tuberculosis (MDR-TB) presents additional, unique challenges for those who suffer from this debilitating disease. Existing drug treatments are multifactorial and complex with lengthy treatment regimens, complicated administration, and toxic secondary effects. The costly treatment of drug- resistant TB can take up to two years and presents significant challenges to health systems, payers, and patients. Recognizing that significant hearing loss can be a side effect of the current treatment regimen for MDR-TB, there is a need to closely monitor patients undergoing treatment with existing and new drug therapies.
Continue Reading